Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 106,655 shares, a decrease of 56.6% from the February 26th total of 245,983 shares. Based on an average daily trading volume, of 105,670 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.1% of the company’s shares are short sold.

Aprea Therapeutics Stock Performance

Shares of Aprea Therapeutics stock opened at $0.67 on Thursday. The firm has a market cap of $7.68 million, a PE ratio of -0.34 and a beta of 1.42. The business’s 50 day simple moving average is $0.77 and its 200 day simple moving average is $1.07. Aprea Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.34.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The firm had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%. As a group, equities research analysts predict that Aprea Therapeutics will post -2.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, January 21st. Zacks Research upgraded shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. HC Wainwright reissued a “buy” rating and set a $4.00 price objective (down from $5.00) on shares of Aprea Therapeutics in a research note on Thursday, January 29th. Finally, Wedbush decreased their price objective on shares of Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $5.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.67% of Aprea Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.